Correction: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis (RMD Open (2019) 5 (e000898) DOI: 10.1136/rmdopen-2019-000898)

1. In panels A (mTSS) and B (ES) for the RA-BEGIN graphs, the symbol (‡) indicating the significance level for the comparison between the baricitinib 4-mg and baricitinib 4-mg plus MTX treatment groups (denoting p≤0.05) should be over the 1 year time point, not the 2 year time point in both graphs. 2. In panel A (mTSS) for RA-BEAM, for the adalimumab versus placebo comparison at 2 years, the significance should have been shown as ++ (p≤0.01) and not +++ (p≤0.001). 3. In the Results text, p.8, line 12 (relating to Figure 3, panel A) '⋯baricitinib treatment groups (0.21±0.01⋯' should read: '⋯baricitinib treatment groups (0.21±0.10⋯' (Figure Presented).